Cargando…

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer

PURPOSE: The recent publication of the ACOSOG Z1031 trial results demonstrated that Ki-67 proliferation marker-based neoadjuvant endocrine therapy response monitoring could be used for tailoring the use of adjuvant chemotherapy in ER+HER2-negative breast cancer patients. In this paper, we describe t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goncalves, Rodrigo, DeSchryver, Katherine, Ma, Cynthia, Tao, Yu, Hoog, Jeremy, Cheang, Maggie, Crouch, Erika, Dahiya, Neha, Sanati, Souzan, Barnes, Michael, Sarian, Luis Otávio Zanatta, Olson, John, Allred, Donald Craig, Ellis, Matthew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543203/ https://www.ncbi.nlm.nih.gov/pubmed/28612227 http://dx.doi.org/10.1007/s10549-017-4329-y

Ejemplares similares

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
por: Ellis, Matthew J., et al.
Publicado: (2017)

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
por: Chen, Rui, et al.
Publicado: (2018)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Use of Ultrasound and Ki–67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy
por: Liebscher, Sean C., et al.
Publicado: (2023)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy
por: He, Jun, et al.
Publicado: (2023)

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)

Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
por: Reis, Joana, et al.
Publicado: (2020)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
por: Cheang, Maggie C. U., et al.
Publicado: (2009)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
por: Ingolf, Juhasz-Böss, et al.
Publicado: (2014)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer
por: Imaizumi, Ken, et al.
Publicado: (2019)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
por: Smith, Ian, et al.
Publicado: (2020)

Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial
por: Reis, Joana, et al.
Publicado: (2021)

Protein bomarkers Ki67, HOXC10 and HOXC11 for the prediction of response to endocrine treatment in breast cancer
por: Soon, YH, et al.
Publicado: (2015)

Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future
por: La Rosa, Stefano
Publicado: (2023)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
por: Burcombe, Russell, et al.
Publicado: (2006)

Immunolocalization of Ki-67 in different periodontal conditions
por: Preethi, Penubolu Lakshmi, et al.
Publicado: (2014)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

ki67 nuclei detection and ki67-index estimation: a novel automatic approach based on human vision modeling
por: Barricelli, Barbara Rita, et al.
Publicado: (2019)

Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group
por: Boyaci, Ceren, et al.
Publicado: (2021)

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
por: Selmani, Zohair, et al.
Publicado: (2022)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer
por: LIN, QI, et al.
Publicado: (2013)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy
por: Elmahs, Aya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ldjiq4nglq82bim4khdce3gkkl